IL-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis

Immunology Letters

Volumn 140, Issue 1-2, 2011, Pages 97-103

  Park, Young Eun ^a   Woo, Yun Ju ^b   Park, Seong Hu ^a   Moon, Young Mee ^b   Oh, Hye Jwa ^b   Kim, Ju In ^c   Jin, Hua Shu ^d   Baek, Seung Hoon ^a   Kim, Geun Tae ^e   Lee, Jun Hee ^f   Cho, Mi La ^b   Kim, Sung Il ^a  

^a Pusan National University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d MUDANJIANG MEDICAL UNIVERSITY   (China)

^e Kosin University   (South Korea)

^f Choonhae Hospital   (South Korea)

Author keywords

Cadherin 11; IL 17; NF kB; Rheumatoid arthritis; Synovial fibroblast

Indexed keywords

CADHERIN; CADHERIN 11; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 7; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVITIS; UPREGULATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CADHERINS; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-17; MICE; MICE, KNOCKOUT; SYNOVIAL MEMBRANE;

EID: 80051789900     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.07.003     Document Type: Article

References (27)

1. Muller-Landner U., Pap T., Gay R.E., Neidhart M., Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005, 1:102-110.
2. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin-17. Nat Immunol 2005, 6:1133-1141.
3. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
4. Lubberts E., Joosten L.A., Oppers B., van den Bersselaar L., Coenen-de Roo C.J., Kolls J.K., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
5. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
6. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
7. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
8. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
9. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
10. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-R795.
11. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996, 84:345-357.
12. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995, 7:619-627.
13. Lee D.M., Kiener H.P., Agarwal S.K., Noss E.H., Watts G.F., Chisaka O., et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007, 315:1006-1010.
14. Kiener H.P., Niederreiter B., Lee D.M., Jimenez-Boj E., Smolen J.S., Brenner M.B. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum 2009, 60:1305-1310.
15. Vandooren B., Cantaert T., ter Borg M., Noordenbos T., Kuhlman R., Gerlag D., et al. Tumor necrosis factor alpha drives cadherin-11 expression in rheumatoid inflammation. Arthritis Rheum 2008, 58:3051-3062.
16. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
17. Lee J.H., Cho M.L., Kim J.I., Moon Y.M., Oh H.J., Kim G.T., et al. Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol 2009, 36:684-692.
18. Van Meurs J.B.J., Van Lent P.L.E.M., Joosten L.A.B., Van der Kraan P.M., Van den Berg W.B. Quantification of mRNA levels in joint capsule and articular cartilage of the murine knee joint by RT-PCR Kinetics of stromelysin and IL-1 mRNA levels during arthritis. Rheumatol Int 1997, 16:197-205.
19. Lipsky P.E. Why does rheumatoid arthritis involve the joints?. N Engl J Med 2007, 356(24):9-2420.
20. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
21. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α by human macrophages. J Immunol 1998, 160:3513-3521.
22. Rhu S., Lee J.H., Kim S.I. IL-17 increases the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006, 25:16-20.
23. Chabaud M., Page G., Miossec P. Enhancing effect of IL-1, IL-17, and TNF-α on macrophage inflammatory protein-3α production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001, 167:6015-6020.
24. Katz Y., Nadiv O., Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6 and 8 in skin and synovial fibroblasts: a possible role as a fine-tuning cytokine in inflammation processes. Arthritis Rheum 2001, 44:2176-2184.
25. Chabaud M., Miossec P. The combination of tumor necrosis factor α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44:1293-1303.
26. Nakae S., Saijo S., Horai R., Sudo K., Mori S., Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003, 100:5986-5990.
27. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.